Falanga V: Classifications for wound bed preparation and stimulation of chronic wounds. .Wound Repair Regen 8::347. ,2000. .
Mustoe TA, O’Shaughnessy K, Kloeters O: Chronic wound pathogenesis and current treatment strategies: a unifying hypothesis. .Plast Reconstr Surg 117: (suppl):35S. ,2006. .
Marston WA: Risk factors associated with healing chronic diabetic foot ulcers: the importance of hyperglycemia. .Ostomy Wound Manage 52::26. ,2006. .
Paquette D, Falanga V: Leg ulcers. .Clin Geriatr Med 18::77. ,2002. .
Veves A, Falanga V, Armstrong DG, et al: Graftskin, a human skin equivalent, is effective in the management of noninfected neuropathic diabetic foot ulcers: a prospective randomized multicenter clinical trial: Apligraf Diabetic Foot Ulcer Study. .Diabetes Care 24::290. ,2001. .
Lee KH: Tissue-engineered human living skin substitutes: development and clinical application. .Yonsei Med J 41::774. ,2000. .
Bello YM, Falabella AF, Eaglstein WH: Tissue-engineered skin: current status in wound healing. .Am J Clin Dermatol 2::305. ,2001. .
Marston WA: Dermagraft, a bioengineered human dermal equivalent for the treatment of chronic non-healing diabetic foot ulcer. .Expert Rev Med Devices 1::21. ,2004. .
Mansbridge J, Liu K, Patch R, et al: Three-dimensional fibroblast culture implant for the treatment of diabetic foot ulcers: metabolic activity and therapeutic range. .Tissue Eng 4::403. ,1998. .
Mansbridge J: Skin substitutes to enhance wound healing. .Expert Opin Investig Drugs 7::803. ,1998. .
Marston WA, Hanft J, Norwood P, et al: The efficacy and safety of Dermagraft in improving the healing of chronic diabetic foot ulcers: results of a prospective randomized trial. .Diabetes Care 26::1701. ,2003. .
Hanft JR, Surprenant MS: Healing of chronic foot ulcers in diabetic patients treated with a human fibroblast-derived dermis. .J Foot Ankle Surg 41::291. ,2002. .
Browne AC, Vearncombe M, Sibbald RG: High bacterial load in asymptomatic diabetic patients with neurotrophic ulcers retards wound healing after application of Dermagraft. .Ostomy Wound Manage 47::44. ,2001. .
Allenet B, Paree F, Lebrun T, et al: Cost-effectiveness modeling of Dermagraft for the treatment of diabetic foot ulcers in the French context. .Diabetes Metab 26::125. ,2000. .
Zaulyanov L, Kirsner RS: A review of a bi-layered living cell treatment (Apligraf) in the treatment of venous leg ulcers and diabetic foot ulcers. .Clin Interventions Aging 2::93. ,2007. .
De SK, Reis ED, Kerstein MD: Wound treatment with human skin equivalent. .JAPMA 92::19. ,2002. .
Trent JF, Kirsner RS: Tissue engineered skin: Apligraf, a bi-layered living skin equivalent. .Int J Clin Pract 52::408. ,1998. .
Donohue KG, Carson P, Iriondo M, et al: Safety and efficacy of a bilayered skin construct in full-thickness surgical wounds. .J Dermatol 32::626. ,2005. .
Brem H, Balledux J, Bloom T, et al: Healing of diabetic foot ulcers and pressure ulcers with human skin equivalent: a new paradigm in wound healing. .Arch Surg 135::627. ,2000. .
Newton DJ, Khan F, Belch JJ, et al: Blood flow changes in diabetic foot ulcers treated with dermal replacement therapy. .J Foot Ankle Surg 41::233. ,2002. .
Healing chronic wounds: technologic solutions for today and tomorrow. .Adv Skin Wound Care 13: (suppl):4. ,2000. .
Edmonds M: Apligraf in the treatment of neuropathic diabetic foot ulcers. .Int J Low Extrem Wounds 8::11. ,2009. .
Steinberg JS, Edmonds M, Hurley DP Jr, et al: Confirmatory data from EU study supports Apligraf for the treatment of neuropathic diabetic foot ulcers. .JAPMA 100::73. ,2010. .
Molecule of the month: Apligraf living human skin equivalent. .Drug News Perspect 11::43. ,1998. .
Dolynchuk K, Hull P, Guenther L, et al: The role of Apligraf in the treatment of venous leg ulcers. .Ostomy Wound Manage 45::34. ,1999. .
Fagrell B, Jorneskog G, Intaglietta M: Disturbed microvascular reactivity and shunting: a major cause for diabetic complications. .Vasc Med 4::125. ,1999. .
Redekop WK, McDonnell J, Verboom P, et al: The cost effectiveness of Apligraf treatment of diabetic foot ulcers. .PharmacoEconomics 21::1171. ,2003. .
Langer A, Rogowski W: Systematic review of economic evaluations of human cell-derived wound care products for the treatment of venous leg and diabetic foot ulcers. .BMC Health Serv Res 9::115. ,2009. .
McCallon SK, Knight CA, Valiulus JP, et al: Vacuum-assisted closure versus saline-moistened gauze in the healing of postoperative diabetic foot wounds. .Ostomy Wound Manage 46::28. ,2000. .
Armstrong DG, Lavery LA, Abu-Rumman P, et al: Outcomes of subatmospheric pressure dressing therapy on wounds of the diabetic foot. .Ostomy Wound Manage 48::64. ,2002. .
Eginton MT, Brown KR, Seabrook GR, et al: A prospective randomized evaluation of negative-pressure wound dressings for diabetic foot wounds. .Ann Vasc Surg 17::645. ,2003. .
Blume PA, Walters J, Payne W, et al: Comparison of negative pressure wound therapy using vacuum-assisted closure with advanced moist wound therapy in the treatment of diabetic foot ulcers: a multicenter randomized controlled trial. .Diabetes Care 31::631. ,2008. .
Armstrong DG, Lavery LA: Negative pressure wound therapy after partial diabetic foot amputation: a multi-centre, randomised controlled trial. .Lancet 366::1704. ,2005. .
Apelqvist J, Armstrong DG, Lavery LA, et al: Resource utilization and economic costs of care based on a randomized trial of V.A.C. therapy in the treatment of diabetic foot wounds. .Am J Surg 195::782. ,2008. .
Kuffler DP: Hyperbaric oxygen therapy: an overview. .J Wound Care 19::77. ,2010. .
Goldman RJ: Hyperbaric oxygen therapy for wound healing and limb salvage: a systematic review. .Pm R 1::471. ,2009. .
Abidia A, Laden G, Kuhan G, et al: The role of hyperbaric oxygen therapy in ischaemic diabetic lower extremity ulcers: a double-blind randomised-controlled trial. .Eur J Vasc Endovasc Surg 25::513. ,2003. .
Kalani M, Jorneskog G, Naderi N, et al: Hyperbaric oxygen (HBO) therapy in treatment of diabetic foot ulcers: long-term follow-up. .J Diabetes Complications 16::153. ,2002. .
Kranke P, Bennett M, Roeckl-Wiedmann I, et al: Hyperbaric oxygen therapy for chronic wounds. .Cochrane Database Syst Rev 2::CD004123. ,2004. .
Londahl M, Katzman P, Nilsson A, et al: Hyperbaric oxygen therapy facilitates healing of chronic foot ulcers in patients with diabetes. .Diabetes Care 33::998. ,2010. .
Grolman RE, Wilkerson DK, Taylor J, et al: Transcutaneous oxygen measurements predict a beneficial response to hyperbaric oxygen therapy in patients with nonhealing wounds and critical limb ischemia. .Am Surg 67::1072. ,2001. .
Fife CE, Buyukcakir C, Otto GH, et al: The predictive value of transcutaneous oxygen tension measurement in diabetic lower extremity ulcers treated with hyperbaric oxygen therapy: a retrospective analysis of 1,144 patients. .Wound Repair Regen 10::198. ,2002. .
Chuck AW, Hailey D, Jacobs P, et al: Cost-effectiveness and budget impact of adjunctive hyperbaric oxygen therapy for diabetic foot ulcers. .Int J Technol Assess Health Care 24::178. ,2008. .
Badiavas EV, Falanga V: Treatment of chronic wounds with bone marrow-derived cells. .Arch Dermatol 139::510. ,2003. .
Deng J, Petersen BE, Steindler DA, et al: Mesenchymal stem cells spontaneously express neural proteins in culture and are neurogenic after transplantation. .Stem Cells 24::1054. ,2006. .
Fathke C, Wilson L, Hutter J, et al: Contribution of bone marrow-derived cells to skin: collagen deposition and wound repair. .Stem Cells 22::812. ,2004. .
McFarlin K, Gao X, Liu YB, et al: Bone marrow-derived mesenchymal stromal cells accelerate wound healing in the rat. .Wound Repair Regen 14::471. ,2006. .
Bauer SM, Goldstein LJ, Bauer RJ, et al: The bone marrow-derived endothelial progenitor cell response is impaired in delayed wound healing from ischemia. .J Vasc Surg 43::134. ,2006. .
Badiavas EV, Ford D, Liu P, et al: Long-term bone marrow culture and its clinical potential in chronic wound healing. .Wound Repair Regen 15::856. ,2007. .
Falanga V, Iwamoto S, Chartier M, et al: Autologous bone marrow-derived cultured mesenchymal stem cells delivered in a fibrin spray accelerate healing in murine and human cutaneous wounds. .Tissue Eng 13::1299. ,2007. .
Steed DL, Diabetic Ulcer Study Group: Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity diabetic ulcers. .J Vasc Surg 21::71. ,1995. .
Veves A, Sheehan P, Pham HT: A randomized, controlled trial of Promogran (a collagen/oxidized regenerated cellulose dressing) vs standard treatment in the management of diabetic foot ulcers. .Arch Surg 137::822. ,2002. .
Gentzkow GD, Iwasaki SD, Hershon KS: Use of Dermagraft, a cultured human dermis, to treat diabetic foot ulcers. .Diabetes Care 19::350. ,1996. .
Cavanagh PR, Lipsky BA, Bradbury AW, et al: Treatment for diabetic foot ulcers. .Lancet 366::1725. ,2005. .
Armstrong DG, Boulton AJ: Pressure offloading and “advanced” wound healing: isn’t it finally time for an arranged marriage?. Int J Low Extrem Wounds 3::184. ,2004. .
Brem H, Balledux J, Sukkarieh T, et al: Healing of venous ulcers of long duration with a bilayered living skin substitute: results from a general surgery and dermatology department. .Dermatol Surg 27::915. ,2001. .
Wound repair and regeneration is a highly complex combination of matrix destruction and reorganization. Although major hurdles remain, advances during the past generation have improved the clinician’s armamentarium in the medical and surgical management of this problem. The purpose of this article is to review the current literature regarding the pragmatic use of three of the most commonly used advanced therapies: bioengineered tissue, negative-pressure wound therapy, and hyperbaric oxygen therapy, with a focus on the near-term future of wound healing, including stem cell therapy. (J Am Podiatr Med Assoc 100(5): 385–394, 2010)